CHARLOTTESVILLE, VA — Monday, February 9, 2004 — David G. Kalergis, JD/MBA, CEO of Diffusion Pharmaceuticals LLC, today announced that the company has received a $1.2 million grant (N00014-04-C-0146) from the Office of Naval Research (ONR) to support the transition of its novel small-molecule drug, trans sodium crocetinate (TSC), from animal to human testing. More [...]

CHARLOTTESVILLE, VA –Tuesday, February 3, 2004 — Diffusion Pharmaceuticals LLC, a drug-development company commercializing its novel small-molecule drug, trans sodium crocetinate (TSC), announced that David G. Kalergis, JD/MBA, joined the company as Chief Executive Officer, effective January 25, 2004. Mr. Kalergis will report to Diffusion Pharmaceuticals’ Board of Directors. The company also announced that Dr. [...]